World Health Organization & Regeneron Pharmaceuticals

World Health Organization: The World Health Organization recommended prioritizing three experimental treatments and several vaccine candidates for the Bundibugyo strain of Ebola, and is working with authorities to design and implement clinical trials.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

World Health Organization: The World Health Organization has declared the Ebola outbreak a public health emergency of international concern, providing funds, dispatching teams, and coordinating global response efforts while expressing deep concern over the outbreak's scale and speed.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.